Less Ads, More Data, More Tools Register for FREE

IP Group's WaveOptics completes £20m fundraising

Tue, 11th Dec 2018 07:44
(Sharecast News) - IP Group's portfolio company WaveOptics, which designs and manufactures diffractive waveguides for use in Augmented Reality (AR) wearables, has completed a £20m fundraising.The round was led by Octopus Ventures and supported by existing shareholders including IP Group, Robert Bosch Venture Capital and Gobi Partners as well as new investors Goertek and Optimas Capital Partners.Following completion of the first tranche of the financing round, IP Group's direct undiluted beneficial stake of 19.9% in WaveOptics is valued at £15.2m, which represents a direct unrealised fair value gain to of £7.6m. IP Group committed £3.7m to the fundraising.Robert Bahns, partner of technology at IP Group, said: "WaveOptics is making excellent progress and we believe the company has the best solution both from a commercial and technical standpoint for providing the key component in AR devices. This is being demonstrated by the level of engagement with its key customers."The funds will be used to scale up WaveOptics' operations on a national and international basis, as it builds a large volume manufacturing supply chain to meet customer demand from the Asian and US markets.The business is also investing in its overseas infrastructure having recently opened offices in Los Angeles and Taipei, with plans to open a new office in Beijing in 2019.IP said the funding round represents the largest AR hardware fundraise in Europe this year."The company is in advanced discussions with potential new shareholders and strategic partners about a second stage investment," it said. Ip Group

Shares in this article

Related News

WINNERS & LOSERS: Howden's acquisition; B&M signals recovery on track
3 Jun 2026

WINNERS & LOSERS: Howden's acquisition; B&M signals recovery on track

(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Wednesday.

IP Group cheers trial results for Enterprise drug candidate
12 May 2026

IP Group cheers trial results for Enterprise drug candidate

(Alliance News) - IP Group PLC on Monday noted positive test results for a cystic fibrosis treatment developed by one of its portfolio firms.

IN BRIEF: IP Group names Michael Queen as next chair, succeeding Flint
7 May 2026

IN BRIEF: IP Group names Michael Queen as next chair, succeeding Flint

IP Group PLC - London-based investor in "breakthrough" science and technology firms - Appoints Michael Queen as chair designate, and as a non-executi...

Corporate News Ip Group + 1 more share